ANI Pharmaceuticals Inc
ANIP97.480USD
+2.125+2.23%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
2.12BMarket Cap
LossP/E TTM
More Details of ANI Pharmaceuticals Inc Company
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
Company Info
Ticker SymbolANIP
Company nameANI Pharmaceuticals Inc
IPO dateMay 04, 2000
CEOMr. Nikhil Suresh Lalwani
Number of employees897
Security typeOrdinary Share
Fiscal year-endMay 04
Address210 Main Street West
CityBAUDETTE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code56623
Phone12186343500
Websitehttps://www.anipharmaceuticals.com/
Ticker SymbolANIP
IPO dateMay 04, 2000
CEOMr. Nikhil Suresh Lalwani
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
61.19K
-2.72%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
26.96K
+19.17%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
61.19K
-2.72%
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.94%
The Vanguard Group, Inc.
5.87%
Meridian Venture Partners
4.68%
Millennium Management LLC
4.63%
Global Alpha Capital Management Ltd.
3.97%
Other
69.91%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.94%
The Vanguard Group, Inc.
5.87%
Meridian Venture Partners
4.68%
Millennium Management LLC
4.63%
Global Alpha Capital Management Ltd.
3.97%
Other
69.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.50%
Investment Advisor/Hedge Fund
22.33%
Hedge Fund
18.31%
Individual Investor
7.74%
Private Equity
4.68%
Research Firm
3.66%
Corporation
2.94%
Bank and Trust
1.72%
Pension Fund
1.64%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
505
24.45M
112.92%
-1.14M
2025Q1
511
24.19M
111.77%
-1.42M
2024Q4
489
23.75M
109.53%
-1.38M
2024Q3
473
23.30M
110.79%
+2.44M
2024Q2
446
19.77M
94.29%
-402.06K
2024Q1
424
18.72M
89.20%
-877.00K
2023Q4
409
18.10M
88.69%
-881.29K
2023Q3
396
18.38M
91.57%
-127.77K
2023Q2
370
17.73M
90.91%
+852.82K
2023Q1
341
15.70M
87.63%
-1.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.44M
11.27%
-89.22K
-3.53%
Mar 31, 2025
The Vanguard Group, Inc.
1.18M
5.44%
-132.90K
-10.14%
Mar 31, 2025
Meridian Venture Partners
1.16M
5.38%
-255.00K
-17.97%
Mar 11, 2025
Millennium Management LLC
1.12M
5.16%
+298.32K
+36.45%
May 30, 2025
Global Alpha Capital Management Ltd.
735.59K
3.4%
+111.04K
+17.78%
Mar 31, 2025
State Street Global Advisors (US)
714.57K
3.3%
-22.72K
-3.08%
Mar 31, 2025
Deep Track Capital LP
700.00K
3.23%
+50.96K
+7.85%
Mar 31, 2025
Esjay L.L.C,
632.62K
2.92%
-200.00K
-24.02%
Mar 14, 2025
Citadel Advisors LLC
723.33K
3.34%
+131.74K
+22.27%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
631.56K
2.92%
-54.17K
-7.90%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
SPDR S&P 600 Small Cap Growth ETF
0%
WisdomTree US SmallCap Fund
0%
SPDR Portfolio Small Cap ETF (SPSM)
0%
iShares U.S. Pharmaceuticals ETF
0%
iShares Core S&P Small-Cap ETF
0%
Invesco S&P SmallCap Health Care ETF
0%
Invesco Pharmaceuticals ETF
0%
Vanguard S&P Small-Cap 600 Growth Index Fund
0%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
View more
SPDR S&P 600 Small Cap Growth ETF
Proportion0%
WisdomTree US SmallCap Fund
Proportion0%
SPDR Portfolio Small Cap ETF (SPSM)
Proportion0%
iShares U.S. Pharmaceuticals ETF
Proportion0%
iShares Core S&P Small-Cap ETF
Proportion0%
Invesco S&P SmallCap Health Care ETF
Proportion0%
Invesco Pharmaceuticals ETF
Proportion0%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0%
SPDR S&P Pharmaceuticals ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
